Journal of Hematology and Oncology Research

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Journal of Hematology and Oncology Research-Cancer-Bachir Benarba


Department of Biology
University of Mascara

Send an Email

Bachir Benarba


Department of Biology,
Daculty of Sciences of Nature and Life,
Pole Sidi Said, Mascara (29000), Algeria,

Research Interests:

Medicinal plants, Cancer, Molecular biology, Phytochemistry, Cancer epidemiology


  • Bachir Benarba, PhD, is Professor of Biochemistry and Cell Biology at the department of Biology, University of Mascara, Algeria. 
  • He’s the chief of this department since October 2013. 
  • He was Technical Director of international project with “Centro de Estudios Rurales Y y de Agricultura Internacional, Spain. Dr Bachir Benarba works on identification of Algerian plants used in the treatment of cancer. 
  • He identified two Algerian plants with strong anticancer and apoptogenic activity, and clarified the molecular mechanism of these activities. 
  • He carries out also ethnobotanical studies in different regions of Algeria. 
  • He manages a research project named “Valorization and identification of new anticancer active molecules from Aristolochia longa. 
  • He is the author of many technical and vulgarization documents on cancer.  
  • He has reviewed and published many international articles. 
  • He also advised more than 40 master and other dissertation’s degrees.


  • Lower p66Shc promoter methylation in subjects with chronic renal failure
  • Phytochemical Profile, Antioxidant and Anti-Inflammatory Activities of Ephedra alata Decne Growing in South Algeria
  • New insight on nutrition and COVID-19 pandemic
  • What about incorporating selenium in the therapeutic regimen of SARS-CoV-2?